
RenovoRx (RNXT) Stock Forecast & Price Target
RenovoRx (RNXT) Analyst Ratings
Bulls say
RenovoRx Inc has demonstrated a notable increase in revenue, reporting $422,000 in Q2, a significant rise from $197,000 in Q1. The company is projected to experience substantial revenue growth, with expectations of reaching $1.3 million in 2025 and $4.5 million in 2026. This anticipated growth reflects the strong market potential of RenovoRx's proprietary Trans-Arterial Micro-Perfusion therapy platform, designed to address high unmet medical needs in cancer treatment.
Bears say
RenovoRx's financial performance reflects ongoing challenges, evidenced by a revenue of only $0.3 to $0.4 million coupled with a net loss of $2.9 million, resulting in an earnings per share (EPS) of $(0.08), which aligns with consensus estimates but underscores a lack of profitability. The company's focus on treating pancreatic cancer, which has a dismal 5-year survival rate of only 12%, raises questions regarding the market viability of its therapeutic approaches amidst significant unmet medical needs. Despite some potential for growth, the overarching risk factors and persistent financial losses contribute to a negative outlook for RenovoRx's stock.
This aggregate rating is based on analysts' research of RenovoRx and is not a guaranteed prediction by Public.com or investment advice.
RenovoRx (RNXT) Analyst Forecast & Price Prediction
Start investing in RenovoRx (RNXT)
Order type
Buy in
Order amount
Est. shares
0 shares